Atypical antipsychotics for the treatment of ICU delirium

Journal of Intensive Care Medicine

Volumn 27, Issue 6, 2012, Pages 354-361

  Gilchrist, Neil A ^a,b   Asoh, Ifeoma ^a,b   Greenberg, Bruce ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

atypical antipsychotics; delirium; olanzapine; quetiapine; risperidone

Indexed keywords

AMIODARONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CLOZAPINE; DOFETILIDE; ERYTHROMYCIN; FLUCONAZOLE; HALOPERIDOL; LEVOFLOXACIN; METHADONE; METOCLOPRAMIDE; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SOTALOL; THIORIDAZINE; VORICONAZOLE; ZIPRASIDONE;

AKATHISIA; CRITICALLY ILL PATIENT; DELIRIUM; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG SUBSTITUTION; EXTRAPYRAMIDAL SYMPTOM; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INTENSIVE CARE UNIT; METABOLIC DISORDER; MORTALITY; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; TORSADE DES POINTES; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DELIRIUM; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE;

EID: 84868120474     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066611403110     Document Type: Review

References (74)

1. Epidemics 2. Smith WD, ed. Cambridge, MA: Harvard University Press ; 1994:
2. Miller RR, Ely EW. Delirium and cognitive dysfunction in the intensive care unit. Curr Psychiatry Rep. 2007 ; 9 (1). 26-34
3. Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA. 2001 ; 286 (21). 2703-2710
4. Lin SM, Liu CY, Wang CH, et al. The impact of delirium on the survival of mechanically ventilated patients. Crit Care Med. 2004 ; 32 (11). 2254-2259
5. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001 ; 29 (7). 1370-1379
6. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009 ; 301 (15). 489-499
7. Van Eijk MM, van Marum RJ, Klijn IA, de Wit N, Kesecioglu J, Slooter AJ. Comparison of delirium assessment tools in a mixed intensive care unit. Crit Care Med. 2009 ; 37 (6). 1881-1885
8. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004 ; 291 (14). 1753-1762
9. Thomason JW, Shintani A, Peterson JF, Pun BT, Jackson JC, Ely EW. Intensive care unit delirium is an independent predictor of longer hospital stay: a prospective analysis of 261 non-ventilated patients. Crit Care. 2005 ; 9 (4). R375 - R381
10. Young CC, Flanagan EM. Delirium: the struggle to vanquish an ancient foe. Crit Care Med. 2010 ; 38 (2). 693-694
11. Jackson JC, Hart RP, Gordon SM, Shintani A, Truman B, May L, Ely EW. Six-month neuropsychological outcome of medical intensive care unit patients. Crit Care Med. 2003 ; 31 (4). 1226-1234
12. Fick DM, Agostini JV, Inouye SK. Delirium superimposed on dementia: a systematic review. J Am Geriatr Soc. 2002 ; 50 (10). 1723-1732
13. Pun BT, Ely EW. The importance of diagnosing and managing ICU delirium. Chest. 2007 ; 132 (2). 624-636
14. Luetz A, Heymann A, Radtke FM, et al. Different assessment tools for intensive care unit delirium: which score to use?. Crit Care Med. 2010 ; 38 (2). 409-418
15. Inouye SK, Bogardus ST, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999 ; 340 (9). 669-676
16. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007 ; 298 (22). 2644-2653
17. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002 ; 30 (1). 119-141
18. Lopez-Munoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull. 2009 ; 79 (2). 130-141
19. Practice guideline for the treatment of patients with delirium. Am J Psychiatry. 1999 ; 156 (suppl 5). 1-20
20. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005 ; 7 (6). 268-274
21. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm. 2000 ; 57 (3). 238-258
22. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988 ; 45 (9). 789-796
23. Alvir JJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis-incidence and risk factors in the United States. N Eng J Med. 1993 ; 329 (3). 162-167
24. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics Part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother. 1999 ; 33 (1). 73-84
25. Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther. 2002 ; 24 (1). 21-37
26. Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics. 2006 ; 47 (3). 264-268
27. Eker SS, Sarandol A, Akkaya C, Sivrioglu EY, Kirli S. The potential relationship between QTc prolongation and ziprasidone treatment: three cases. J Psychopharmacol. 2009 ; 23 (8). 993-996
28. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 ; 37 (3). 177-193
29. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007 ; 46 (5). 359-388
30. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine. An atypical antipsychotic. Clin Pharmacokinet. 2001 ; 40 (7). 509-522
31. Risperdal (risperidone) tablets package insert. Titusville, NJ: Janssen Ortho LLC ; 2009:
32. Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmcol. 2010 ; 50 (6). 659-66
33. Winans E. Aripiprazole. Am J Health Sys Pharm. 2003 ; 60 (23). 2437-2445
34. Girard TD, Pandharipande PP, Carson SS, et al. Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Crit Care Med. 2010 ; 38 (2). 428-437
35. Devlin JW, Roberts RJ, Fong JJ, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med. 2010 ; 38 (2). 419-427
36. Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med. 2004 ; 30 (3). 444-449
37. Han C, Kim Y. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics. 2004 ; 45 (4). 297-301
38. Peritogiannis V, Stefanou E, Lixouriotis C, Gkogkos C, Rizos D. Atypical antipsychotics in the treatment of delirium. Psychiatry Clin Neurosci. 2009 ; 63 (5). 623-631
39. Sipahimalani A, Masand P. Use of risperidone in delirium: case reports. Ann Clin Psychiatry. 1997 ; 9 (2). 105-107
40. Sipahimilani A, Masand P. Olanzapine in the treatment of delirium. Psychosomatics. 1998 ; 39 (5). 422-430
41. Straker DA, Shapiro PA, Muskin PR. Aripiprazole in the treatment of delirium. Psychosomatics. 2006 ; 47 (5). 385-390
42. Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics. 2002 ; 43 (3). 175-182
43. Smith MA, McCoy R, Hamer-Maansson J, Brecher M. Rapid dose escalation with quetiapine. J Clin Psychopharmacol. 2005 ; 25 (4). 331-335
44. Mittal D, Jimerson NA, Neely EP, et al. Risperidone in the treatment of delirium: results from a prospective open-label trial. J Clin Psychiatry. 2004 ; 65 (5). 662-667
45. Maldonado JR. Intravenous versus oral haloperidol: an evaluation of the incidence of extra-pyramidal symptoms. Psychosomatics. 2000 ; 41 (2). 169-170
46. Brown CS, Farmer RG, Soberman JE, et al. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin Pharmcokinet. 2004 ; 43 (1). 33-56
47. Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: part II adverse effects, drug interactions, and costs. Ann Pharmacother. 1999 ; 33 (2). 210-217
48. Pfizer Inc. Briefing Document for Zeldox Capsules (ziprasidone HCl). Submitted to FDA Psychopharmacological Drugs Advisory Committee; July 19, 2000. Available athttp://www.fda.gov.ohrms/dockets/ac/00/backgrd/3619b1a.pdf. Accessed March 8, 2010
49. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 1999 ; 60 (suppl 10). 5-14
50. Breitbarb W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics. 2002 ; 43 (3). 175-182
51. Sharif ZA. Overview of safety and tolerability of atypical antipsychotics used in primary care. J Clin Psychistry. 2003 ; 5 (suppl 3). 14-21
52. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001 ; 345 (19). 1359-1367
53. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006 ; 354 (5). 449-461
54. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA. 2003 ; 290 (15). 2041-2047
55. Elias A, Hofflich H. Abnormalities in glucose metabolism in patients with schizophrenia treated with atypical antipsychotic medications. Am J Med. 2008 ; 121 (2). 98-104
56. Reynolds G, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther. 2010 ; 125 (1). 169-179
57. Devinsky O, Honigfield G, Patin J. Clozapine-related seizures. Neurology. 1991 ; 41 (3). 369-371
58. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007 ; 164 (6). 870-876
59. Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother. 2009 ; 43 (4). 785-791
60. Gleason PP, Congliaro RL. Neuroleptic malignant syndrome with risperidone. Pharmacotherapy. 1997 ; 17 (3). 617-621
61. Najara JE, Enikeev ID. Risperidone and neuroleptic malignant syndrome: a case report. J Clin Psychiatry. 1995 ; 56 (11). 534-535
62. Filice GA, Mcdougall BC, Ercan-Fang N, et al. Neuroleptic malignant syndrome associated with olanzapine. Ann Pharmacother. 1998 ; 32 (11). 1158-1159
63. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 ; 100 (1). 4-22
64. Perkins NA, Murphy JE, Malone DC, Armstrong EP. Performance of drug-drug interaction software for personal digital assistants. Ann. Pharmacother. 2006 ; 40 (5). 850-855
65. Dallenbach MF, Bovier PA, Desmeules J. Detecting drug interactions using personal digital assistants in an out-patient clinic. Q J Med. 2007 ; 100 (11). 691-697
66. Sharif ZA. Pharmcokinetics, metabolism, and drug-drug interactions of atypical antipsychotics in special populations. Primary Care Companion J Clin Psychiatry. 2003 ; 5: 22-25
67. Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother. 2003 ; 37 (5). 687-694
68. Miller DO. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care companion. J Clin Psychiatry. 2004 ; 6 (suppl 2). 3-7
69. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrpyramidal function. CNS Drugs. 2002 ; 16 (1). 23-45
70. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007 ; 21 (11). 911-936
71. Patel JK, Buckley PF, Woolson S, Hamer RM, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res. 2009 ; 111 (1-3). 9-16
72. Tholakanahalli VN, Potti A, Hanley JF, Merliss AD. Fluconazole-induced Torsade de pointes. Ann Pharmacother. 2001 ; 35 (4). 432-434
73. Owens RC, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006 ; 43 (12). 1603-1611
74. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QT interval, torsades de pointes, and sudden death. Am J Psychiatry. 2001 ; 158 (11). 1774-1782